Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Common Equity: 2019-2024

Historic Common Equity for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $24.4 million.

  • Eton Pharmaceuticals' Common Equity rose 44.71% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 44.71%. This contributed to the annual value of $24.4 million for FY2024, which is 57.83% up from last year.
  • According to the latest figures from FY2024, Eton Pharmaceuticals' Common Equity is $24.4 million, which was up 57.83% from $15.5 million recorded in FY2023.
  • Over the past 5 years, Eton Pharmaceuticals' Common Equity peaked at $24.4 million during FY2024, and registered a low of $13.1 million during FY2022.
  • In the last 3 years, Eton Pharmaceuticals' Common Equity had a median value of $15.5 million in 2023 and averaged $17.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first decreased by 25.82% in 2022, then soared by 57.83% in 2024.
  • Yearly analysis of 5 years shows Eton Pharmaceuticals' Common Equity stood at $15.7 million in 2020, then climbed by 12.56% to $17.6 million in 2021, then dropped by 25.82% to $13.1 million in 2022, then grew by 18.34% to $15.5 million in 2023, then skyrocketed by 57.83% to $24.4 million in 2024.